This clinical trial is investigating orforglipron (also called LY3502970) compared to insulin glargine in adults who have Type 2 Diabetes along with obesity or being overweight and who are at increased risk for cardiovascular (heart and blood vessel) problems. Type 2 Diabetes is a condition where the body doesn’t use insulin properly, resulting in high blood sugar levels. People in this study will have evidence of heart disease and will already be taking diabetes medications.
The purpose of this study is to determine if daily oral orforglipron is as effective as insulin glargine (an injectable insulin) in preventing major heart-related events in these patients. The study will look at outcomes such as myocardial infarction (heart attack), stroke, hospitalization for unstable angina (chest pain), and death related to heart disease.
This is a Phase 3, open-label study, which means participants and researchers will know which treatment is being given. Participants will either take orforglipron once daily by mouth or use insulin glargine injections while continuing their existing diabetes medications. The study will monitor their health status over time to compare the safety and effectiveness of these two treatment approaches.



Austria
Czechia
Germany
Greece
Italy
Romania
Slovakia
Spain